June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Characteristics of three types of neovascular age-related macular degeneration and treatment strategies of anti-VEGF agents in real-world clinical setting: A multicenter cohort study by J-CREST
Author Affiliations & Notes
  • Keisuke Yoneda
    Boei Ika Daigakko, Tokorozawa, Saitama, Japan
  • Tsutomu Yasukawa
    Nagoya Shiritsu Daigaku Daigakuin Igaku Kenkyuka Igakubu, Nagoya, Aichi, Japan
  • Hiroto Terasaki
    Kagoshima Daigaku Daigakuin Ishigaku Sogo Kenkyuka, Kagoshima, Kagoshima, Japan
  • yuki yamamoto
    Hyogo Ika Daigaku, Nishinomiya, Hyogo, Japan
  • tatsuya jujo
    Saint marianna University school of medicine, Kawasaki, Japan
  • makiko wakuta
    Yamaguchi Daigaku Igakubu Daigakuin Igakukei Kenkyuka, Ube, Yamaguchi, Japan
  • hisashi matsubara
    Mie Daigaku Daigakuin Igakukei Kenkyuka Igakubu, Tsu, Mie, Japan
  • yoshinori mitamura
    Tokushima University graduate school, Tokushima, Japan
  • Aki Katou
    Nagoya Shiritsu Daigaku Daigakuin Igaku Kenkyuka Igakubu, Nagoya, Aichi, Japan
  • Mineo Kondo
    Mie Daigaku Daigakuin Igakukei Kenkyuka Igakubu, Tsu, Mie, Japan
  • kazuhiro kimura
    Yamaguchi Daigaku Igakubu Daigakuin Igakukei Kenkyuka, Ube, Yamaguchi, Japan
  • Hitoshi takagi
    Kawasaki Tama Eye Clinic, Kanagawa, Japan
  • Fumi Gomi
    Hyogo Ika Daigaku, Nishinomiya, Hyogo, Japan
  • Taiji Sakamoto
    Kagoshima Daigaku Daigakuin Ishigaku Sogo Kenkyuka, Kagoshima, Kagoshima, Japan
  • Masaru Takeuchi
    Boei Ika Daigakko, Tokorozawa, Saitama, Japan
  • Footnotes
    Commercial Relationships   Keisuke Yoneda None; Tsutomu Yasukawa None; Hiroto Terasaki None; yuki yamamoto None; tatsuya jujo None; makiko wakuta None; hisashi matsubara None; yoshinori mitamura None; Aki Katou None; Mineo Kondo None; kazuhiro kimura None; Hitoshi takagi None; Fumi Gomi None; Taiji Sakamoto None; Masaru Takeuchi None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2231. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Keisuke Yoneda, Tsutomu Yasukawa, Hiroto Terasaki, yuki yamamoto, tatsuya jujo, makiko wakuta, hisashi matsubara, yoshinori mitamura, Aki Katou, Mineo Kondo, kazuhiro kimura, Hitoshi takagi, Fumi Gomi, Taiji Sakamoto, Masaru Takeuchi; Characteristics of three types of neovascular age-related macular degeneration and treatment strategies of anti-VEGF agents in real-world clinical setting: A multicenter cohort study by J-CREST. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2231.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Characteristics of three types of neovascular age-related macular degeneration and treatment strategies of anti-VEGF agents in real-world clinical setting: A multicenter cohort study by J-CREST

Methods : This is a retrospective, multi-centre cohort study. Medical records of 602 patients (320 typical AMD, 247 PCV, and 35 RAP) were retrospectively investigated for age, gender, best corrected visual acuity at baseline and 1 year after the treatment, spectral-domain optical coherence tomography (SD-OCT) findings of intraretinal fluid (IRF), subretinal fluid (SRF), serous pigment epithelial detachment (PED), hard exudates, subretinal hyperreflective material (SHRM), and subretinal hemorrhage (SRH), anti-vascular endothelial growth factor (VEGF) agents, and the number of vitreal injections.

Results : Mean age was 75.3 ± 10.4 years in tAMD group, 74.1 ± 9.7 years in PCV group, and 82.0 ± 6.9 years in RAP, and there was significant difference between 3 groups. Female ratio was also significantly higher in RAP group compared with other 2 groups. Regarding SD-OCT findings, frequencies of SRF and SRH were less, those of IRF and hard exudates were more in RAP group than in tAMD or PCV group. Serous PED was the most in PCV group followed by RAP group and tAMD group. The ratio of aflibercept vs. ranibizumab was 72 : 28 in tAMD group, 69 : 31 in PCV group, and 63 : 37 in RAP group, however there was no significant difference in the number of injections of anti-VEGF agent. Both LogMAR at baseline and 1 year after the initiation of treatment were significantly higher in RAP group (0.64 ± 0.43 and 0.56 ± 0.46) than in tAMD group (0.44 ± 0.48 and 0.37 ± 0.56) and in PCV group (0.43 ± 0.55 and 0.27 ± 0.43), and LogMAR VA was significantly improved by anti-VEGF treatment for 1 year compared with baseline in tAMD group and PCV group but not in RAP group.

Conclusions : Frequencies of individual OCT findings were significantly different between tAMD, PCV, and RAP groups, and ranibizumab was more employed for RAP group. SRF and SRH were less in RAP group, however the visual prognosis was worse.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×